I found the editorial by Licinio and Wong 1 entitled 'Launching the war on mental illness' very interesting. The authors discussed the need for a coordinated and well planned assault on mental illness, and suggested that the present time for this 'war' to be launched is propitious. They suggested that this endeavour has to be done using the processes of translational science, and keeping this in mind, they discussed the modalities involved.
I would like to discuss the role of epigenetics in this endeavour. Epigenetics includes molecular mechanisms like DNA methylation, histone modifications, and RNA-mediated regulation of gene expression. Epigenetics is presently a very active area of research in biomedicine the world over and is proving to be pervasive in its relevance, and monumental in its importance, to mental illness. For example, there is increasing evidence that epigenetics plays a key role in various aspects of normal behaviour 2 and In the pathogenesis of virtually every type of mental illness. [2] [3] [4] Epigenetics could also play a key role in several ways in the clinical management of mental illness: (1) In the diagnosis of mental illness: epigenetic changes in the body may prove to be useful in the clinical diagnosis of mental illness by providing suitable biomarkers. 5 (2) In the prevention of mental illness since abnormal epigenetic mechanisms of gene expression are potentially reversible. 6 Prevention of mental illness could be attempted by one or more of the interventional modalities described below (items 3 to 7). (3) In the pharmacotherapy of mental illness: epigenetic therapy, the use of drugs to correct epigenetic defects, could be used for the treatment of mental illness. At present most work on epigenetic therapy is focussed on the design and development of drugs targeting DNA methylation and drugs inhibiting the enzyme histone deacetylase. 6 These drugs are being investigated for use in mental illness.
2 (4) In the nutritional management of mental illness. 7 For example, methyl donors like L-methylfolate and S-adenosylmethionine which donate a methyl group in the body and hence enhance DNA methylation, are being investigated for use in mental illness. 7 (5) In psychotherapy: there is evidence that psychotherapy exerts its beneficial effects on patients with mental illness by acting by epigenetic mechanisms. 7,8 (6) Electoconvulsive therapy (ECT): there is accumulating evidence that ECT exerts its beneficial effects on patients at least partially by changing epigenetic mechanisms of gene expression in the brain in treated patients.
2,9 (7) Physical exercise, which is known to benefit patients with mental illness: there is accumulating evidence that physical exercise exerts its beneficial effects on the mind and body at least partially by epigenetic mechanisms. 10 From the preceding information, it appears that epigenetics has a prominent role in the pathogenesis and clinical management of mental illness. Hence, I suggest that epigenetics should be given due attention in the 'war' on mental illness. I suggest that epigenetics should be one of the spearheads of this endeavour.
The effect of FTO rs9939609 on major depression differs across MDD subtypes 1 reported in this journal that the fat mass and obesity-associated protein (FTO) rs9939609 A variant was associated with a lower risk of major depressive disorder (MDD) independently from BMI. However, clinical heterogeneity may contribute to variability of results in association studies investigating the biologic and genetic underpinnings of MDD. Using data from the Netherlands Study of Depression and Anxiety (NESDA) we showed 2 in a previous issue of the journal that depressed patients can be divided using data-driven techniques into a 'typical' (termed also 'melancholic') and an 'atypical' subtype differentiated mainly by the direction of change in vegetative symptoms (that is, appetite, weight and sleep) and associated with distinct biological correlates, pointing to a partially distinct pathophysiological and genetic liability. Therefore, considering our prior observations that obesity and increased appetite are more prevalent in atypical depression, and obesity rates are not different or even less prevalent as compared with controls in typical depression, 2, 3 it can be expected that the FTO variant shows different associations across MDD subtypes. As an exemplification of our hypothesis, we performed the same association test between rs9939609 and MDD as in the paper of Samaan et al. 1 In addition, we explored whether this association differed across clinical subtypes.
Our sample consisted of 4350 unrelated participants (42.0 ± 14.1 years of age, 63.6% females) of European ancestry from the NESDA 4 (1544 cases and 336 controls) and from the Netherlands Twin Registry 5 (2470 controls). Genotyping and imputation methods and QC checks have been extensively detailed elsewhere. 6 Briefly, genotyping has been subsequently performed on multiple chip platforms in (partially overlapping) different subsets of the total sample (Affymetrix-Perlegen 5.0, Illumina 370 K, Illumina 660 K, Illumina Omni 1 M and Affymetrix 6.0) and data were imputed using the 1000 Genomes phase 1 INTEGRATED RELEASE version 3 ALL panel. 7 rs9939609 was typed in some of the panels used for imputation and all post-imputation QC criteria were met; r2hat value was 0.99, indicating an almost perfect correlation between the imputed genotype and its true underlying genotype. Minor allele frequency was 0.38. The diagnosis of lifetime and/or current MDD according to DSM-IV was ascertained using the Composite Interview Diagnostic Instrument. 8 Among 1178 cases with available symptom-level data, depressive symptoms were used as indicator variables in a latent class analyses approach as previously described; 2 we identified two classes characterized by high severity, typical (20%) and atypical (21.7%), and a class of moderate severity (58.3%). Height and weight were measured to calculate body mass index (BMI) in kg m . The association between rs9939609 (additive model) and different outcomes were tested using linear and (multinomial) logistic regressions adjusting for age, sex and population stratification (three principal components). Analyses were performed in SAS (v. 9.2, SAS Institute, Cary, NC, USA) and R (v. 3.0.1, R Project for Statistical Computing).
The characteristics of the study sample and the main results for the association tests are shown in Table 1 . As compared with controls, cases were more likely to be female and had higher BMI. Consistently with the results of Samaan et al.,
1 the rs9939609 A variant was confirmed to be positively associated with BMI (β = 0.40, s.e. = 0.09, P = 1.56E − 05) and BMI was positively associated with presence of MDD (odds ratio (OR) = 1.08; 95% confidence interval (CI) = 1.07-1.10; P = 5.47E − 24). However, in contrast to the study by Samaan et al.,
1 the FTO variant was associated with a higher probability of having MDD (P = 0.023) but the association was no longer significant after additional adjustment for BMI (Table 1) . When considering MDD subtypes, results from a multinomial logistic regression showed that, as compared with controls, the rs9939609 A variant was associated with a 1.42-fold increased odd of having atypical MDD (P = 1.84E − 04). Typical and moderate subtypes were not associated with rs9939609. After additional adjustment for BMI, the association between the FTO variant and atypical subtype, despite a 19% reduction in effect size, remained statistically significant (P = 0.003). We confirmed the significant association of rs9939609 with atypical subtype via permutation analyses. After comparing the actual atypical MDD cases with controls in binary logistic regression, we sampled from the overall cases 256 patients (N of atypical) 10 000 times and compared them again against controls. The results indicated that obtaining a lower Pvalue was unlikely to have occurred by chance (empirical-P = 0.002).
Taken together, these findings suggest that MDD subtypes contribute to variability of results in genetic association studies. In contrast to the study by Samaan et al. 1 we found a positive association between the FTO rs9939609 A variant and MDD, but this was completely driven by the atypical MDD subtype, independently from BMI. The profile of MDD subtypes in the studies included in the paper by Samaan et al.
1 is unknown, but we could hypothesize that the conclusions about the relationship between FTO and depression may have differed when considering the specific clinical subtypes as compared with the overall MDD diagnosis.
Not considering the heterogeneity of depression in genetic associations studies may contribute to discrepant or blurred effect sizes. Recent simulations studies confirmed that phenotypic heterogeneity may have negatively impacted the results of large collaborative genetic studies. 9 Disentangling MDD heterogeneity by characterizing subtypes with different clinical and pathophysiological profiles may benefit the research on genetic determinants of depression.
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